Zymeworks Inc. (ZYME) Stock Score, Valuation & Financial Research
Zymeworks Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 32/100.
Quick answer for ZYME
Zymeworks Inc. currently has a Wall Street Score of 32/100. The stored market price is $26.86. Its financial score is 49/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Zymeworks Inc. does
Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer. Its pipeline features two primary experimental treatments: zanidatamab, a cutting-edge bispecific antibody currently undergoing Phase 1 and Phase 2 studies for various malignancies such as those affecting the biliary tract, gastroesophageal region (adenocarcinomas), breast, and colon; and ZW49, an antibody-drug conjugate targeting two sites on the human epidermal growth factor receptor 2 (HER2), which is in Phase 1 trials for advanced or spreading tumors that express HER2. Zymeworks maintains significant alliances with several pharmaceutical leaders, including Merck Sharp & Dohme Research Ltd., Eli Lilly and Company, Bristol-Myers Squibb company, GlaxoSmithKline Intellectual Property Development Ltd., Dai
ZYME financial snapshot
- Wall Street Score:
- 32/100
- Current price:
- $26.86
- Market capitalization:
- $1.98B
- Revenue:
- $81.3M
- Net income:
- $-102.7M
- Free cash flow:
- $-34.5M
- Cash:
- $244.3M
- Total debt:
- $17.0M
- EPS:
- -1.08
- Financial score:
- 49/100
- Valuation score:
- 0/100
- Revenue score:
- 15/100
What stands out
- Reported year-over-year revenue growth is -0.2%.
- Free cash flow is $-34.5M, showing cash burn in the current stored period.
- The balance sheet shows $244.3M of cash versus $17.0M of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 49/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research ZYME
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.